Hematopoietic progenitor cell transplantation in multiple myeloma

• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Hegenbart, Ute [VerfasserIn]
• Verfasst von: Haas, Rainer [VerfasserIn]
• Verfasst von: Hunstein, Werner [VerfasserIn]
• Titel: Hematopoietic progenitor cell transplantation in multiple myeloma
• Verf.angabe: H. Goldschmidt, U. Hegenbart, R. Haas, W. Hunstein
• Jahr: 1995
• Umfang: 6 S.
• Fussnoten: Elektronische Reproduktion der Druck-Ausgabe 11. Mai 2009 ; Gesehen am 15.05.2025
• Titel Quelle: Enthalten in: Onkologie
• Ort Quelle: Basel : Karger, 1978
• Jahr Quelle: 1995
• Band/Heft Quelle: 18(1995), 6, Seite 518-523
• ISSN Quelle: 1423-0240
• DOI: doi:10.1159/000218652
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1925774902

Abstract

The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy with dose-escalated alkylating agents (i. e. melphalan 140 mg/m2) induced higher remission rates than conventional treatment. If followed by allogeneic or autologous hematopoietic progenitor cell transplantation, the hematotoxicity of the described dose-escalated treatment could be reduced. Results of transplantation trials are summarized and discussed. The transplantation of autologous peripheral blood progenitor cells results in a faster hematopoietic reconstitution and a decreased high-dose therapy-related morbidity compared to autologous bone marrow and should therefore be preferred. Although the randomized French myeloma trial showed a significant survival advantage for patients following autologous transplantation, further randomized prospective studies are required to evaluate the role of blood progenitor cell transplantation after high-dose treatment in multiple myeloma. Prognostical factors and future treatment modalities for myeloma are discussed.